UCB: Pipeline, Products, Performance, Potential

Date: January 22, 2010
Pages: 82
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U872A398D1AEN

Download PDF Leaflet

UCB: Pipeline, Products, Performance, Potential
UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of CNS disorders, allergy/respiratory diseases, immune and inflammatory disorders, plus oncology. Headquartered in Brussels, Belgium, it has over 12,000 employees worldwide.

The Group has production and packaging facilities in Belgium, Switzerland, the US, Japan, Germany, India, Italy, Spain and South Korea and sells in more than 40 countries on all continents. During 2005, the Group disposed of the Surface Specialties business segment and transformed itself into a pure biopharmaceutical company. The recent acquisitions of Celltech and Schwarz Pharma should help establish UCB as one the leading biopharmaceutical companies in Europe.

The divestiture of the Surface Specialities segment in 2005 has negatively impacted total company revenue insubsequent fiscal years despite strong growth in the Pharmaceutical segment, which was boosted by the acquisition of Celltech in 2004. The purchase of Schwarz Pharma, which was completed in July 2007, helped return company revenue in fiscal 2007 to positive growth for the first time since 2004. However, in fiscal 2008, revenue declined once more, this time due to the loss of market exclusivity for the key products Keppra and, in particular, Zyrtec.

UCB’s current top-selling product is Keppra, a leading epilepsy therapy, which has recorded peak sales of over EUR 1 billion. The loss of patent protection is expected to heavily impact sales and prior to the acquisition of Schwarz, it appeared UCB would not have the resources to offset these losses. However, UCB now sells Schwarz-developed Neupro, a novel Parkinson’s disease treatment recently approved in the US and Europe. Sales of Neupro are forecast to reach EUR 166 million in 2013, and combined with launches and sales for promising late-stage pipeline products such as Cimzia and Vimpat, the impact of falling sales of Keppra is expected to be considerably dampened.

Nonetheless, long-term growth remains threatened by this patent loss and UCB will have to make significant investment in R&D and seek to in-licence new products to further expand the product portfolio. The acquisition of Schwarz brings with it substantial expertise and research infrastructure in the field of biotechnology and in particular the treatment of CNS disorders. Consequently, UCB now has the tools required to overcome the difficulties anticipated with Keppra and to further re-enforce its position as one of the leading biopharmaceutical companies in Europe.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.


Key product analysis and forecasting
Central Nervous System
  Keppra (levetiracetam)
  Metadate CD/Equasym XL (methylphenidate)
  Neupro (rotigotine)
  Vimpat (lacosamide)
  Cimzia (certolizumab pegol; formerly CDP870)
  Xyzal/Xusal (levocetirizine)
  Zyrtec/Reactine (cetirizine)


A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Subsidiaries and joint ventures
Skip to top

Ask Your Question

UCB: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: